180 related articles for article (PubMed ID: 25721936)
1. Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.
Salas J; Liu T; Lu Q; Kulman JD; Ashworth T; Kistanova E; Moore N; Pierce GF; Jiang H; Peters R
Thromb Res; 2015 May; 135(5):970-6. PubMed ID: 25721936
[TBL] [Abstract][Full Text] [Related]
2. Prolonged in-vivo half-life of factor VIIa by fusion to albumin.
Weimer T; Wormsbächer W; Kronthaler U; Lang W; Liebing U; Schulte S
Thromb Haemost; 2008 Apr; 99(4):659-67. PubMed ID: 18392323
[TBL] [Abstract][Full Text] [Related]
3. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
Dumont JA; Liu T; Low SC; Zhang X; Kamphaus G; Sakorafas P; Fraley C; Drager D; Reidy T; McCue J; Franck HW; Merricks EP; Nichols TC; Bitonti AJ; Pierce GF; Jiang H
Blood; 2012 Mar; 119(13):3024-30. PubMed ID: 22246033
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
6. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Metzner HJ; Pipe SW; Weimer T; Schulte S
Thromb Haemost; 2013 Nov; 110(5):931-9. PubMed ID: 24178510
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
8. Prolonged activity of factor IX as a monomeric Fc fusion protein.
Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
10. Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S9-S12. PubMed ID: 27288065
[TBL] [Abstract][Full Text] [Related]
11. Eloctate for hemophilia A.
Med Lett Drugs Ther; 2015 Oct; 57(1479):143-4. PubMed ID: 26445206
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
Agersø H; Tranholm M
Haemophilia; 2012 Jul; 18 Suppl 5():6-10. PubMed ID: 22757678
[TBL] [Abstract][Full Text] [Related]
13. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
14. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
Ducore JM; Miguelino MG; Powell JS
Expert Rev Hematol; 2014 Oct; 7(5):559-71. PubMed ID: 25142322
[TBL] [Abstract][Full Text] [Related]
15. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
[TBL] [Abstract][Full Text] [Related]
16. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa.
Schulte S
Thromb Res; 2008; 122 Suppl 4():S14-9. PubMed ID: 18929521
[TBL] [Abstract][Full Text] [Related]
17. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa.
Karpf DM; Sørensen BB; Hermit MB; Holmberg HL; Tranholm M; Bysted BV; Groth AV; Bjørn SE; Stennicke HR
Thromb Res; 2011 Aug; 128(2):191-5. PubMed ID: 21429564
[TBL] [Abstract][Full Text] [Related]
18. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
[TBL] [Abstract][Full Text] [Related]
19. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
20. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
